NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and July 25, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form ...

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=103503&from=4 CLASS PERIOD: January 8, 2024 to July 25, ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=103185&from=3 CLASS PERIOD: January 8, 2024 to J ...

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its business performance and growth prospects during the Class Period from January 8, 2024, to July 25, 2024 [1][2]. Group 1: Allegations Against DexCom - The complaint claims that DexCom's statements about growth and anticipated margins were overly optimistic, primarily due to reliance on attracting new customers [2]. - It is alleged that DexCom faced challenges in maintaining successful existing distribution channels [2]. - As a result, the statements made by DexCom regarding its business operations and future prospects were materially false and misleading [2]. Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to apply to be appointed as a lead plaintiff representative for the class [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected DexCom investors to contact them for more information [4][5]. - The firm has a strong reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].

Group 1 - A lawsuit has been filed against DexCom, Inc. and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] - DexCom develops glucose monitoring systems for diabetes management and aimed to capitalize on growth potential while scaling customer conversion to the new G7 platform [2] - Following disappointing earnings results for Q2 2024, DexCom reduced its full-year revenue guidance from $4.35 billion to a range of $4 billion to $4.05 billion, leading to a significant stock price decline of 38% [2] Group 2 - The stock price of DexCom closed at $107.85 per share on July 25, 2024, and dropped to $66.60 per share by the next trading day [2] - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and has a strong track record, including recovering over $900 million from Tesla's Board of Directors [3][4]

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=102414&from=4 CLASS PERIOD: January 8, 2024 to July 25, ...

NEW YORK, Sept. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

No need to break the bank to get in on these excellent companies.With $200, one can afford many lottery tickets, one of which could be a winner. However, the odds of winning meaningful money by playing the lottery are minuscule. Investing in the stock market might not make anyone rich overnight the way the lottery could, but even with $200, investors can acquire shares of companies in excellent positions to deliver outsized returns over the long run. Let's consider two stocks trading well below $200 that ha ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 13, 2024 (GLOBE NEW ...